Download MendeleyAtropisomerism Observed in Galactose-Based Monosaccharide Inhibitors of Galectin-3 Comprising 2-Methyl-4-phenyl-2,4-dihydro-3 H -1,2,4-triazole-3-thione.
Yoon, D.S., Liu, C., Jalagam, P.R., Feng, J., Wang, W., Swidorski, J.J., Xu, L., Hartz, R.A., Nair, S.K., Beno, B.R., Panda, M., Ghosh, K., Kumar, A., Sale, H., Shah, D., Mathur, A., Ellsworth, B.A., Cheng, D., Regueiro-Ren, A.(2024) J Med Chem 67: 14184-14199
- PubMed: 39102502
- DOI: https://doi.org/10.1021/acs.jmedchem.4c01008
- Primary Citation of Related Structures:
8Z1S, 8Z1T, 8Z25, 8ZUV - PubMed Abstract:
Galectin-3 (Gal-3) is a carbohydrate binding protein that has been implicated in the development and progression of fibrotic diseases. Proof-of-principal animal models have demonstrated that inhibition of Gal-3 is a potentially viable pathway for the treatment of fibrosis─with small molecule Gal-3 inhibitors advanced into clinical trials. We hereby report the discovery of novel galactose-based monosaccharide Gal-3 inhibitors comprising 2-methyl-4-phenyl-2,4-dihydro-3 H -1,2,4-triazole-3-thione (compound 20 ) and 4-phenyl-4 H -1,2,4-triazole (compound 15 ). Notably, hindered rotation caused by steric interaction between the 3-thione and ortho -trifluoromethyl group of compounds 20 , 21 induced formation of thermodynamically stable atropisomers. Distinct X-ray cocrystal structures of 20 and 21 were obtained, which clearly demonstrated that the configuration of 21 proscribes a key halogen bonding σ-hole interaction of 3-chloro with carbonyl oxygen of Gly182, thereby leading to significant loss in potency. Ultimately, 20 and 15 were evaluated in mouse pharmacokinetic studies, and both compounds exhibited oral exposures suitable for further in vivo assessment.
Organizational Affiliation:
Research and Early Development, Bristol Myers Squibb, P.O. Box 5400, Princeton, New Jersey 08543-5400, United States.
